LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report) today and set a price target of $3.45. The company’s shares opened today at $3.57.
According to TipRanks, Katkhuda is an analyst with an average return of -22.5% and a 21.74% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Vera Therapeutics, and Cincor Pharma.
Eledon Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.73.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.39 and a one-year low of $2.03. Currently, Eledon Pharmaceuticals has an average volume of 15.59K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
Read More on ELDN:
- Eledon to prioritize resources on tegoprubart in kidney transplantation
- Eledon Pharmaceuticals, eGenesis collaborate for use of tegoprubart
- Eledon Pharmaceuticals Provides Business and Pipeline Updates
- C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
